Xiao et al. found that METTL3 facilitates γ δ T17 cell-mediated proinflammatory response in imiquimod-induced psoriasis-like mouse model, and METTL3 is considered a potential target for treating γ δ T17 cell-mediated excessive inflammation (Xiao et al., 2023). This evidence concerns the gene METTL3 and psoriasis.